By Mill Chart
Last update: Dec 12, 2023
Consider NOVO-NORDISK A/S-SPONS ADR (NYSE:NVO) as an affordable growth stock, identified by our stock screening tool. NYSE:NVO is showcasing impressive growth figures and is well-positioned in terms of profitability, solvency, and liquidity. Moreover, it seems to be priced reasonably. Let's dive deeper into the analysis.
Every stock receives a Growth Rating from ChartMill, ranging from 0 to 10. This rating assesses various growth aspects, including historical and projected EPS and revenue growth. NYSE:NVO boasts a 7 out of 10:
An integral part of ChartMill's stock analysis is the Valuation Rating, which spans from 0 to 10. This rating evaluates diverse valuation factors, including price to earnings and cash flows, while considering the stock's profitability and growth. NYSE:NVO has received a 5 out of 10:
ChartMill utilizes a Health Rating to assess stocks, scoring them on a scale of 0 to 10. This rating takes into account a variety of liquidity and solvency ratios, both in absolute terms and in comparison to industry peers. NYSE:NVO has earned a 7 out of 10:
ChartMill's Profitability Rating offers a unique perspective on stock analysis, providing scores from 0 to 10. These ratings consider a wide range of profitability metrics and margins, both in comparison to industry peers and on their own merits. For NYSE:NVO, the assigned 9 is a significant indicator of profitability:
Every day, new Affordable Growth stocks can be found on ChartMill in our Affordable Growth screener.
Check the latest full fundamental report of NVO for a complete fundamental analysis.
This article should in no way be interpreted as advice in any way. The article is based on the observed metrics at the time of writing, but you should always make your own analysis and trade or invest at your own responsibility.
NOVO-NORDISK A/S-SPONS ADR
NYSE:NVO (5/3/2024, 7:09:32 PM)
After market: 123 -0.05 (-0.04%)123.05
-0.97 (-0.78%)
The company delivered solid quarterly results, but its discussion of an investigational drug is what really gave its shares a pop.
These under-the-radar stocks have the potential to reach a $1 trillion valuation by 2030 as they gain momentum in their respective industries.
The Nasdaq regained its 50-day line Friday. The other indexes hit resistance.
Amgen (AMGN) stock is soaring after the company's CEO said he was "very encouraged" by interim data for Amgen's new weight-loss drug.
Stock spinoffs can unlock shareholder value but management sometimes uses them to get rid of unwanted, slow-growing businesses.
The path is clear for even more growth from Novo Nordisk's top two drugs, Ozempic and Wegovy.
NVO earnings call for the period ending March 31, 2024.
NVO stock results show that Novo Nordisk beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024.
Novo Nordisk stock came under mild selling pressure early Thursday, after the company reported Q1 results and lifted guidance.
We love it when our favorite clothes go on sale, so when the market offers us a deal, these are the stocks to buy on dips.
While some retail companies are still thriving, investors would be smart to steer clear of these consumer stocks to avoid.
We also look at the "treasure hunt" economy.